Status:
COMPLETED
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
Lead Sponsor:
Foundation for Liver Research
Conditions:
Hepatitis C
Liver
Eligibility:
All Genders
18-70 years
Brief Summary
Aim To evaluate the effects of peginterferon and ribavirin therapy on the immune response in chronic HCV genotype 1,2 or 3 patients before, during and after treatment. Background Treatment of chron...
Eligibility Criteria
Inclusion
- Male and female patients between 18-70 years of age, with evidence of a chronic hepatitis C - Genotype 1,2 or 3 infection.
- No previous treatment with, peginterferon or conventional interferon plus ribavirin combination therapy.
- Indication for antiviral therapy of hepatitis C according to current clinical guidelines.
- Written informed consent.
Exclusion
- History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study.
- Presence of contra-indications for antiviral therapy with peginterferon or ribavirin.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00422838
Start Date
January 1 2007
End Date
November 1 2010
Last Update
January 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology & Hepatology, Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3015 GD